Skip to Main Content

Paper Details

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.
Hepatology
297
2008
ACH, AG-021541, BILN2061, Boceprevir, HCV, HCV genome sequences, ITMN-191, NS3, NS4A, NS5B polymerase, R155K, R155K protease, R155K protease mutation, SCH6, Telaprevir, drug, hepatitis C, hepatitis C virus, hepatitis C virus (HCV, patients, peginterferon, ribavirin

Datasets

Release 1.2